StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.45−0.03 (-5.40%)

Close on Nov 16, 2026Market cap $124.31MP/E –Yield –

Akebia Therapeutics cash

Cash and short-term investments held at the end of each period.

Akebia Therapeutics's cash was $155.55M at Jun 30, 2026. For fiscal 2025 it was $184.84M, up 245.2% from the year before. Over ten years it grew 2.9% a year on average. The highest annual figure on record is $321.64M in fiscal 2018.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$184.84M+245.2%
FY2024Dec 31, 2024$53.55M+24.8%
FY2023Dec 31, 2023$42.93M-53.9%
FY2022Dec 31, 2022$93.17M-37.8%
FY2021Dec 31, 2021$149.80M-44.2%
FY2020Dec 31, 2020$268.69M+81.9%
FY2019Dec 31, 2019$147.69M-54.1%
FY2018Dec 31, 2018$321.64M+1.2%
FY2017Dec 31, 2017$317.79M+22.1%
FY2016Dec 31, 2016$260.34M+87.7%
FY2015Dec 31, 2015$138.69M+27.3%
FY2014Dec 31, 2014$108.97M+234.7%
FY2013Dec 31, 2013$32.55M+1883.8%
FY2012Dec 31, 2012$1.64M-67.3%
FY2011Dec 31, 2011$5.01M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$155.55M+11.9%
Q1 FY2026Mar 31, 2026$162.64M+41.4%
Q4 FY2025Dec 31, 2025$184.84M+245.2%
Q3 FY2025Sep 30, 2025$166.44M+366.3%
Q2 FY2025Jun 30, 2025$139.00M+237.6%
Q1 FY2025Mar 31, 2025$115.06M+163.8%
Q4 FY2024Dec 31, 2024$53.55M+24.8%
Q3 FY2024Sep 30, 2024$35.69M-25.9%
Q2 FY2024Jun 30, 2024$41.17M-25.5%
Q1 FY2024Mar 31, 2024$43.62M-26.9%
Q4 FY2023Dec 31, 2023$42.93M-53.9%
Q3 FY2023Sep 30, 2023$48.18M-67.4%
Q2 FY2023Jun 30, 2023$55.29M-62.4%
Q1 FY2023Mar 31, 2023$59.67M-66.4%
Q4 FY2022Dec 31, 2022$93.17M-37.8%
Q3 FY2022Sep 30, 2022$147.85M-28.6%
Q2 FY2022Jun 30, 2022$146.98M-40.5%
Q1 FY2022Mar 31, 2022$177.65M-34.9%
Q4 FY2021Dec 31, 2021$149.80M-44.2%
Q3 FY2021Sep 30, 2021$207.20M-23.0%
Q2 FY2021Jun 30, 2021$246.99M-16.4%
Q1 FY2021Mar 31, 2021$272.76M+136.4%
Q4 FY2020Dec 31, 2020$268.69M+81.9%
Q3 FY2020Sep 30, 2020$269.26M+84.9%
Q2 FY2020Jun 30, 2020$295.35M+116.0%
Q1 FY2020Mar 31, 2020$115.37M-31.3%
Q4 FY2019Dec 31, 2019$147.69M-54.1%
Q3 FY2019Sep 30, 2019$145.61M-62.7%
Q2 FY2019Jun 30, 2019$136.77M-66.0%
Q1 FY2019Mar 31, 2019$168.04M-57.2%
Q4 FY2018Dec 31, 2018$321.64M+1.2%
Q3 FY2018Sep 30, 2018$390.14M+18.3%
Q2 FY2018Jun 30, 2018$402.12M+25.1%
Q1 FY2018Mar 31, 2018$393.03M+56.0%
Q4 FY2017Dec 31, 2017$317.79M+22.1%
Q3 FY2017Sep 30, 2017$329.89M+104.5%
Q2 FY2017Jun 30, 2017$321.47M–
Q1 FY2017Mar 31, 2017$251.98M–
Q4 FY2016Dec 31, 2016$260.34M–
Q3 FY2016Sep 30, 2016$161.33M–

More Akebia Therapeutics figures

See a number that looks wrong?